Abstracts tagged "cytokines and rheumatoid arthritis (RA)"

Abstract Number: 1388 • 2013 ACR/ARHP Annual Meeting
Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity
Peter Olsson¹, Elke Theander², Ulf Bergström³, Stefan Jovinge⁴, Lennart Jacobsson³ and Carl Turesson², ¹Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
Background/Purpose: Rheumatoid factor (RF) and other circulating heterophilic antibodies have been shown to interfere with antibody-based immunoassays, in particular with multiplex protein detection platforms. Previous…
Abstract Number: 1286 • 2013 ACR/ARHP Annual Meeting
Anti-Inflammatory Effects Of Tyrosine-Hydroxylase(TH)-Positive Catecholamine Producing Cells In Chronic Arthritis
Zsuzsa Jenei-Lanzl¹, Silvia Capellino², Frieder Kees³ and Rainer H. Straub⁴, ¹Department of Internal Medicine, University Hospital Regensburg, 1Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Regensburg, Germany, ²2Department of Pediatrics, Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA., Baltimore, MD, ³Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany, ⁴Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany
Background/Purpose: In previous studies we have shown that inflammatory processes in experimental arthritis are strongly affected by the sympathetic nervous system (SNS): In the early…
Abstract Number: 932 • 2013 ACR/ARHP Annual Meeting
Hypoxia and Signal Transducer and Activator Of Transcription 3 Signalling Interactions Regulate Pro-Inflammatory Pathways In Rheumatoid Arthritis
Wei Gao¹, Jennifer McCormick¹, Mary Connolly², Emese Balogh², Douglas J. Veale¹ and Ursula Fearon¹, ¹Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ²Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Signal Transducer and Activator of Transcription 3 (STAT3), a critical transcription activator in angiogenesis, plays a crucial role in the pathogenesis of Rheumatoid Arthritis…
Abstract Number: 720 • 2013 ACR/ARHP Annual Meeting
Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber³ and J.a.G. van Roon⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Abatacept is an effective treatment for a subset of rheumatoid arthritis (RA) patients, interfering in the interaction between antigen-presenting cells and T cells preventing…
Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting
Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Kunihiro Yamaoka¹, Satoshi Kubo¹, Koshiro Sonomoto¹, Shintaro Hirata¹, Guy Cavet², Rebecca Bolce², Michael W. Rowe², David Chernoff², Nadine Defranoux², Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.